Accéder au contenu
Merck

NADK is activated by oncogenic signaling to sustain pancreatic ductal adenocarcinoma.

Cell reports (2021-06-17)
Tanya Schild, Melanie R McReynolds, Christie Shea, Vivien Low, Bethany E Schaffer, John M Asara, Elena Piskounova, Noah Dephoure, Joshua D Rabinowitz, Ana P Gomes, John Blenis
RÉSUMÉ

Metabolic adaptations and the signaling events that control them promote the survival of pancreatic ductal adenocarcinoma (PDAC) at the fibrotic tumor site, overcoming stresses associated with nutrient and oxygen deprivation. Recently, rewiring of NADPH production has been shown to play a key role in this process. NADPH is recycled through reduction of NADP+ by several enzymatic systems in cells. However, de novo NADP+ is synthesized only through one known enzymatic reaction, catalyzed by NAD+ kinase (NADK). In this study, we show that oncogenic KRAS promotes protein kinase C (PKC)-mediated NADK phosphorylation, leading to its hyperactivation, thus sustaining both NADP+ and NADPH levels in PDAC cells. Together, our data show that increased NADK activity is an important adaptation driven by oncogenic signaling. Our findings indicate that NADK could serve as a much-needed therapeutic target for PDAC.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps monoclonal anti-vinculine antibody produced in mouse, clone hVIN-1, purified from hybridoma cell culture
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
RéférenceConditionnementDisponibilitéPrixQuantité
100 mg
Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit.
101.00 €
250 mg
Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit.
161.00 €
1 g
Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit.
512.00 €